Navigation Links
NYU Cancer Institute researcher among first NIH EUREKA award recipients
Date:9/3/2008

New York City, NY September 3, 2008 - The National Institutes of Health (NIH) has awarded $42.2 million to fund 38 exceptionally innovative research projects that could have an extraordinarily significant impact on many areas of science. The grants, from a new program called EUREKA (for Exceptional, Unconventional Research Enabling Knowledge Acceleration), targets investigators who are testing novel, unconventional hypotheses or are pursuing major methodological or technical advances. Eureka researchers will receive direct costs of approximately $200,000 per year for up to four years.

Michelle Krogsgaard, Ph.D, assistant professor of pathology at the NYU Cancer Institute, is the first NYU School of Medicine recipient of the EUREKA award. In 2006, Dr. Krogsgaard joined NYU and her work has focused on the different signaling methods T-cells use in the contexts of cancer and autoimmune disease. The EUREKA award will allow Dr. Krogsgaard to explore the complex molecular mechanisms that govern the training and activation of immune cells; specifically, how intracellular signals are generated in T-cells, currently an immunological black box. Dr. Krogsgaard practices an interdisciplinary approach to her research, which incorporates cellular, chemical and structural biology techniques. Through this fresh perspective and multidisciplinary approach, Dr. Krogsgaard aims to build on her previous training to initiate a novel and risky approach to study mechanisms of T-cell signaling and to bolster her controversial hypothesis that structural changes in the receptor complex are important for T-cell signaling. This award will give her the freedom to explore innovative techniques and interdisciplinary approaches that would not be supported by an R01 award.

Using a combination of novel imaging and biophysical techniques, Dr. Krogsgaard investigates how one can manipulate signaling mechanisms in T-cells which could enhance the immune response in patients with HIV or cancer or diminish T-cell activation in patients with autoimmune disease.


'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related biology news :

1. Blood fingerprints for cancer
2. Height linked to risk of prostate cancer development and progression
3. TGen and Washington University researchers discover new approach to treating endometrial cancer
4. Landmark study opens door to new cancer, aging treatments
5. Growth factor predicts poor outcome in breast cancer
6. Researchers discover atomic bomb effect results in adult-onset thyroid cancer
7. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
8. Normalizing tumor vessels to improve cancer therapy
9. CSHL scientists identify new drug target against virulent type of breast cancer
10. Gene therapy anti-cancer research featured in Scientific American
11. Dense tissue promotes aggressive cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... December 5, 2016 The U.S. ... almost $108 billion of revenue and some $890 billion ... spent on global biopharmaceuticals, and this figure is expected ... has lined up these four equities for assessment: Northwest ... Inc. (NASDAQ: ACAD ), Acorda Therapeutics Inc. ...
(Date:12/4/2016)... , Dec. 3, 2016  In five studies being ... (ASH) Annual Meeting and Exposition in San ... methods to improve the delivery of life-saving treatments to ... methods are designed to carry therapies directly to the ... which could provide a substantial advantage over traditional, systemic ...
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... Dec. 2, 2016 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the appointment of ... industry consultant, and private healthcare investor, to its Board ... leader with clinical and strategic experience at the highest ... and CEO. "As one of the world,s leading orthopedic ...
Breaking Biology Technology: